All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Since the turn of the millennium our understanding of the ecological niches and genetic diversity of methicillin-resistant *Staphylococcus aureus* (MRSA) has changed markedly. Several distinct lineages of MRSA are now known to inhabit and cause clinical infections in animals including horses, companion animals (i.e. dogs and cats) and intensively managed livestock \[[@pone.0146034.ref001],[@pone.0146034.ref002]\]. These so-called "animal-adapted" MRSA are a concern for public health as, under certain circumstances, they can colonise and/or cause infections in humans with intimate exposure to animals \[[@pone.0146034.ref001],[@pone.0146034.ref002]\].

Several studies have shown human healthcare workers (HCWs) working with MRSA-colonised patients and veterinarians with routine occupational exposure to animals often have a higher prevalence of MRSA nasal colonisation in comparison to the general public \[[@pone.0146034.ref003],[@pone.0146034.ref004]\]. For instance, the prevalence of ST398 MRSA colonisation amongst livestock veterinarians in Europe is estimated to be greater than 40%, \[[@pone.0146034.ref005],[@pone.0146034.ref006]\] and the prevalence of CC8 MRSA colonisation amongst equine veterinary personnel in North America ranges from 9.7% to 18% \[[@pone.0146034.ref007]--[@pone.0146034.ref009]\]. Moreover, ST22 MRSA has been recovered from 17.9% of companion animal veterinarians in the United Kingdom \[[@pone.0146034.ref010]\]. In a recent Australian study, the prevalence of MRSA nasal colonisation was found to be extremely high among specialist equine veterinarians (21.4%) and well above the average for those veterinarians practicing companion animal medicine only (4.9%) \[[@pone.0146034.ref011]\]. In human medicine in a review of 127 outbreak studies, 4.6% of 33,318 HCWs working with MRSA-positive patients were colonised with MRSA \[[@pone.0146034.ref003]\]. In a recent nasal MRSA colonisation prevalence study on HCWs working in a Western Australian acute care hospital only 3.4% of 1,542 HCWs screened were MRSA colonised. However, 10.7% of HCWs working in high risk MRSA wards were colonised \[[@pone.0146034.ref012]\].

In human medicine the prevalence of HCW colonisation has been shown to be dependent upon the circulating MRSA strain, with different strains varying in their ability to colonise HCWs \[[@pone.0146034.ref013]\]. While previous studies have identified and characterised MRSA strains from horses (CC8), dogs (ST22) and pigs (ST398) in Australia \[[@pone.0146034.ref014]--[@pone.0146034.ref016]\]. In our previous study evaluating the prevalence of MRSA carriage among Australian veterinarians, we identified those veterinarians with horses as a major area of work emphasis had a prevalence of 11.8% and those whose only major emphasis was horses had a prevalence of 21.4%. Veterinarians with dogs and cats as a major activity had a 4.9% prevalence. Whilst prevalence rates for other major activities such as pigs (8.3%), dairy (4.6%), beef cattle (8.1%), avian (10%) and wildlife (3.23%) were also increased, however these were estimated from smaller numbers of respondents \[[@pone.0146034.ref011]\].

In the current study we sought to define the molecular epidemiology of MRSA isolated from Australian veterinarians from our previous study to better understand why some veterinarians have a high prevalence of MRSA \[[@pone.0146034.ref011]\]. This study also aims to place these strains into epidemiological context with strains from other sources (e.g. animals, community-associated and healthcare-associated strains), both in Australia and abroad.

Materials and Methods {#sec002}
=====================

Bacterial isolates {#sec003}
------------------

The study characterised 44 MRSA isolates recovered from the anterior nares of 771 healthy veterinarians sampled during a series of national veterinary conferences in Australia in 2009 \[[@pone.0146034.ref011]\]. As previously described, nasal swabs were obtained from veterinarians attending the Australian Veterinary Association Annual Conference in Darwin (17--22 May 2009), the Australian Pig Veterinarians Conference in Melbourne (22--23 June 2009), the Australian College of Veterinary Scientists Conference on the Gold Coast (2--4 July 2009) and the Bain Fallon Equine Conference at the Sunshine Coast (20--24 July 2009) \[[@pone.0146034.ref011]\]. The recruitment of human subjects into this study was approved by the Human Research Ethics Committee of the Northern Territory Department of Health & Families and Menzies School of Health Research (HREC 09/41). Those who volunteered were provided with background reading on MRSA and recruitment was formalised by obtaining signed consent. Each subject was assigned a coded, unique number and adhesive labels displaying this number were each affixed to the information sheet (retained by each subject), consent form, sterile cotton tipped swab and a receptacle for the swab containing sterile enrichment broth. For the duration of the study, researchers were blinded to the identity of respondents, and respondents who tested positive for MRSA and indicated that they wanted to be informed of their culture results were confidentially notified. Whilst participants completed an online questionnaire as part of the survey, as per the conditions of the human ethics approval (HREC 09/41), their identity and location of practice remained anonymous.

The three major veterinarian occupations that tested positive for MRSA were: equine practice (EP, *n* = 18), companion animal practice (CAP, *n* = 14), and mixed animal practice with both companion animals and equines (MPE, *n* = 6). Six MRSA were isolated from mixed animal practice with companion animals and ruminants but no equines (MP, *n* = 2), pig practice (PP, *n* = 1), ruminant herd consulting practice (HC, *n* = 1), industry veterinarian (pharmaceutical representative) with no clinical practice (IND, *n* = 1), and a veterinary science student with undefined exposure (STU, *n* = 1).

*nuc* and *mecA* characterization {#sec004}
---------------------------------

*Staphylcoccus aureus* species and methicillin resistance were confirmed by the detection of *nuc* (thermostable extracellular nuclease) and *mecA* (methicillin resistance) genes respectively using multiplex PCR. \[[@pone.0146034.ref017]\]

Antimicrobial susceptibility testing {#sec005}
------------------------------------

Antimicrobial susceptibility testing was performed by disk diffusion according to the Clinical and Laboratory Standards Institute (CLSI) recommendations \[[@pone.0146034.ref018]\]. A panel of ten antimicrobial agents was tested: cefoxitin (30μg), chloramphenicol (30μg), ciprofloxacin (5μg), clindamycin (2μg), erythromycin (15μg), fusidic acid (10μg), gentamicin (10μg), mupirocin (5μg) rifampicin (5μg), tetracycline (30 μg), and trimethoprim (5 μg). CLSI interpretive criteria were used for all antimicrobials except fusidic acid and mupirocin. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) break points were used for fusidic acid and mupirocin.\[[@pone.0146034.ref019]\] Isolates displaying resistance to three or more antimicrobial classes were considered to be multidrug-resistant (MDR).

Pulsed-field gel electrophoresis (PFGE) {#sec006}
---------------------------------------

Electrophoresis of chromosomal DNA was performed on all isolates as previously described, using a contour-clamped homogeneous electric field (CHED) DR III system \[[@pone.0146034.ref020]\]. Chromosomal patterns were examined visually, scanned with a Quantity One (Bio-Rad) and digitally analysed using FPQuest (Bio-Rad). *S*. *aureus* strain NCTC 8325 was used as a reference strain.

DNA microarray {#sec007}
--------------

All isolates were analysed using a *S*. *aureus* DNA microarray. Arrays and reagents were obtained from Alere Technologies, Jena Germany. The principle of the assay, related procedures, and a list of targets have been described previously \[[@pone.0146034.ref021]\]. The microarray was used to detect the presence of virulence and antimicrobial resistance genes. Probes for *mecA*, *ugpQ*, *xylR*, and two probes for *mecR* were used for SCC*mec* typing. The last two probes allowed detection and discrimination for untruncated *mecR* and Δ*mecR*, respectively. Probes for the recombinase genes *ccrA1*, *ccrB1*, *ccrA2*, *ccrB2*, *ccrA3*, *ccrB3*, *ccrA4*, *ccrB4* and *ccrC1*; the fusidic acid resistance marker Q6GD50; and the J region proteins, *dcs*, *plsSCC* and the *kdp*-operon also were included. Ambiguous array results were considered negative.

*spa* and *dru* typing {#sec008}
----------------------

Sequence analysis of the protein A gene variable region (*spa*) and the *mec*-associated *dru* region was performed on all isolates as previously described \[[@pone.0146034.ref022],[@pone.0146034.ref023]\]. Chromosomal DNA was prepared using a DNeasy (Qiagen) tissue kit.

Multilocus sequence typing (MLST) {#sec009}
---------------------------------

The MLST for each isolate with a unique PFGE pulsotype or s*pa* type was determined by Illumina Miseq. Genomic DNA libraries were prepared using the Nextera XT kit (Illumina) and sequenced on the 250-bp pair-ended chemistry. DNA sequences collated at <http://saureus.mlst.net/> belonging to 3,044 ST types were downloaded in FASTA format and used as the database in the SRST2 pipeline to match the corresponding MLST profiles to the Illumina sequence data for each isolate \[[@pone.0146034.ref024]\].

Isolates sharing six of seven MLST loci were deemed to belong to the same clonal complex (CC). Double locus variants were included in the same CC only when the linking single locus variant was also present in the MLST database (<http://www.mlst.net/>).

Statistical analyses {#sec010}
--------------------

The strength of association between major occupational emphasis and MRSA clonal complex recovered from veterinarians was assessed by calculating the odds ratio (OR) with 95% confidence intervals (95% CI). An OR greater than unity represents a positive association, while OR less than unity represents a negative association. The magnitude of departure of OR from unity represents the strength of association. P-values (*P*) for assessing the null hypothesis of nil-association between virulence and isolate origin (OR = 1) were calculated using Fisher's exact test and differences were considered significant when *P* ≤ 0.05.

Results {#sec011}
=======

MLST, PFGE, *spa*, SCC*mec* and *dru* types {#sec012}
-------------------------------------------

The isolate collection comprised eight multilocus sequence types (STs) and seven clonal complexes (CCs) ([S1 File](#pone.0146034.s001){ref-type="supplementary-material"}). The clonal lineages included CC1, CC5, CC8, CC22, CC59, CC88, and CC398 ([Table 1](#pone.0146034.t001){ref-type="table"}). Seventeen *spa* types were detected and ten different SCC*mec* and *dru* combinations were observed, with SCC*mec* IV \[2B\]-dt10a being most dominant among the collection (27/44 isolates, 61.4%). The predominant clonal lineages were CC8 (24/44, 54.5%) and CC22 (12/44, 27.3%). CC8 was recovered most frequently from equine only veterinarians (15/18) and included two STs; ST8 (20/24) and ST612 (4/24). All CC8 isolates harboured SCC*mec* IV \[2B\] and had closely related s*pa* and *dru* types, with *spa* t064 *dru* dt10a being most dominant, and by PFGE had a WA20 pulsotype. CC22 was most frequently isolated from companion animal veterinarians (10/14, 71.4%) and consisted of one ST, ST22, which harboured SCC*mec* IV \[2B\]. The isolates were predominantly *spa* type t032, *dru* type dt10a and had an EMRSA-15 PFGE pulsotype. A single isolate from a pig practice veterinarian was identified as ST398-V \[5C2\] (*spa* t1451, *dru* dt11a).

10.1371/journal.pone.0146034.t001

###### Molecular characteristics of methicillin-resistant *Staphylococcus aureus* (*n* = 44) isolated from veterinarians in Australia.

![](pone.0146034.t001){#pone.0146034.t001g}

  Isolate                                                                 PFGE      *spa*    ST (CC)     SCC*mec*      *dru*    Resistance phenotype
  ----------------------------------------------------------------------- --------- -------- ----------- ------------- -------- --------------------------
  **Companion Animal Practice (14)**                                                                                            
  34                                                                      EMRSA15   t032     22 (22)     IV \[2B\]     dt10a    CIP
  253                                                                     EMRSA15   t032     22 (22)     IV \[2B\]     dt10a    CIP
  257                                                                     EMRSA15   t032     22 (22)     IV \[2B\]     dt10a    ERY, CIP
  330                                                                     EMRSA15   t032     22 (22)     IV \[2B\]     dt10a    CIP
  844                                                                     EMRSA15   t032     22 (22)     IV \[2B\]     dt10a    CIP
  428                                                                     EMRSA15   t1625    22 (22)     IV \[2B\]     dt10bw   CIP
  610                                                                     EMRSA15   t3547    22 (22)     IV \[2B\]     dt10a    CIP
  622                                                                     EMRSA15   t9448    22 (22)     IV \[2B\]     dt10a    CIP
  38                                                                      EMRSA15   t10924   22 (22)     IV \[2B\]     dt10a    CIP
  606                                                                     EMRSA15   t10924   22 (22)     IV \[2B\]     dt10a    CIP
  616                                                                     USA100    t242     5 (5)       II \[2A\]     NIL      ERY, CLI, CIP
  580                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, TET, TRM
  673                                                                     WA20      t1171    8 (8)       IV \[2B\]     dt9j     GEN, ERY, TET, RIF
  612                                                                     WA20      t064     8 (8)       V \[5C2\]     dt9aw    GEN, TET, TRM
  **Equine Practice (18)**                                                                                                      
  809                                                                     EMRSA15   t1977    22 (22)     IV \[2B\]     dt10a    CIP
  728                                                                     WA2       t186     78 (88)     IV \[2B\]     dt10a    ERY
  815                                                                     WA2       t186     78 (88)     IV \[2B\]     dt9ah    ERY
  713                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, TET, TRM, RIF
  699                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, TET, TRM, RIF
  718                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10g    GEN, ERY, TET, TRM, RIF
  727                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, TET, TRM
  741                                                                     WA20      t064     8 (8)       IV \[2B\]     dt9j     GEN, ERY, TET, TRM, RIF
  761                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, TET, TRM
  783                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, TET, RIF
  787                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, ERY, TET, TRM, RIF
  823                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, ERY, TET, TRM, RIF
  58                                                                      WA20      t2658    8 (8)       IV \[2B\]     dt10a    GEN, TET, TRM, RIF
  734                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, ERY, TET, TRM, RIF,
  742                                                                     WA20      t064     8 (8)       IV \[2B\]     dt7d     GEN, ERY, TET, TRM, RIF
  822                                                                     WA20      t451     612 (8)     IV \[2B\]     dt7d     GEN, TET, TRM, RIF
  723                                                                     WA20      t723     612 (8)     IV \[2B\]     dt7d     GEN, ERY, TET, TRM, RIF
  778                                                                     WA20      t723     612 (8)     IV \[2B\]     dt7d     GEN, ERY, TET, TRM, RIF
  **Herd Consulting Practice (1)**                                                                                              
  786                                                                     WA2       t186     78 (88)     IV \[2B\]     dt9ah    ERY
  **Industry Veterinarian---Pharmaceutical Representative (1)**                                                                 
  55                                                                      WA20      t064     8 (8)       IV \[2B\]     dt10a    ERY, TET, TRM
  **Mixed Animal Practice (2)**                                                                                                 
  389                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, ERY, TET, TRM, RIF
  570                                                                     WA20      t064     612 (8)     IV \[2B\]     dt7d     GEN,TET, TRM, RIF
  **Mixed Animal Practice with both Companion Animals and Equines (6)**                                                         
  100                                                                     EMRSA15   t032     22 (22)     IV \[2B\]     dt10a    CIP
  773                                                                     WA15      t976     59 (59)     IV \[2B\]&5   dt10a    ERY
  103                                                                     WA2       t690     78 (88)     IV \[2B\]     dt10a    
  747                                                                     WA20      t064     8 (8)       IV \[2B\]     dt10a    GEN, ERY, TRM
  413                                                                     WA20      t064     8 (8)       IV \[2B\]     dt7d     GEN, ERY, TET, TRM, RIF
  716                                                                     WA20      t064     8 (8)       IV \[2B\]     dt7d     GEN, TET, TRM, RIF
  **Pig Practice (1)**                                                                                                          
  516                                                                     ST398     t1451    398 (398)   V \[5C2\]     dt11a    ERY, TET, TRM, CIP, CLI
  **Veterinary Science Student with Undefined Exposure (1)**                                                                    
  698                                                                     WA1       t1853    1 (1)       IV \[2B\]     dt10a    

PFGE: pulsed-field gel electrophoresis pulsotype; *spa*: staphylococcal protein A type; ST: multilocus sequence type; CC: clonal complex; SCC*mec*, staphylococcal chromosome cassette *mec* type; *dru*: direct repeat unit type; CIP: ciprofloxacin; CLI: clindamycin; ERY: erythromycin; GEN: gentamicin; RIF: rifampicin; TET: tetracycline; TRM: trimethoprim.

Mixed practice veterinarians including those with exposure to both companion animals and equines were found to carry ST22-IV \[2B\] (1/6), ST8-IV \[2B\] (3/6), ST59-IV \[2B\] (1/6) and ST78-IV \[2B\] (1/6). CC8 (ST8-IV \[2B\] and ST612-IV \[2B\]) also was carried by mixed practice veterinarians with companion and bovine but no equine exposure and an industry veterinarian who was not exposed to clinical veterinary practice. A veterinary student with undefined exposure carried ST1-IV \[2B\] and a herd consulting veterinarian carried ST78-IV \[2B\].

Antimicrobial resistance phenotypes and genotypes {#sec013}
-------------------------------------------------

More than two-thirds of isolates (32/44, 72.7%) were MDR with resistance influenced by the clone type; ST22-IV \[2B\] (PFGE EMRSA-15) was typically ciprofloxacin-resistant and ST8-IV \[2B\] (PFGE WA20) was typically gentamicin, tetracycline, erythromycin and rifampicin-resistant ([S1 File](#pone.0146034.s001){ref-type="supplementary-material"}). Resistance to erythromycin (20 isolates) was conferred by *erm(A)* (4 isolates) *erm(C)* (15), and *msr(A)*\[macrolide efflux pump\]*/ mph(C)*\[macrolide phosphotransferase\] (1) (Tables [1](#pone.0146034.t001){ref-type="table"} and [2](#pone.0146034.t002){ref-type="table"}). Tetracycline resistance (24 isolates) was conferred by *tet(K)* (2), *tet(M)* (23). One tetracycline-resistant isolate harboured *tetK* and *tetM* genes. Twenty one of the 23 trimethoprim-resistant isolates harboured *dfr* (dihydrofolate reductase mediating trimethoprim resistance). Isolates from equine-specialist veterinarians were frequently resistant to gentamicin (15/18) and rifampicin (10/18). Gentamicin resistance was conferred by *aacA-aphD* (aminoglycosideadenyl-/phosphotransferase) (15). Three gentamicin-resistant isolates also harboured *aadD (aminoglycoside adenyltransferase*). The mechanism conferring rifampicin resistance was not confirmed. Only four of the isolates from companion animal veterinarians were MDR, however, almost all isolates were ciprofloxacin-resistant (11/14). Whole genome sequencing showed ciprofloxacin resistance was due to two point mutations generating from amino acid substitutions Ser80Phe in topoisomerase IV (Grla) and Ser84Leu in gyrase A (GyrA). None of the isolates carried *vanA*, *vanB* or *vanZ* glycopeptide-resistant genes. Furthermore, no isolates tested positive for the resistance determinants *lnu*(A) (lincosamides), *mef*(A) (macrolides), *vat*(A) (virginiamycin), *vga*(A) (streptogramin A, lincosamide, pleuromutilin), *vgb*(A) (virginiamycin-B/pristinamycin), *mupA* (mupirocin), *cat* (chloramphenicol), or *fexA* (phenicols).

10.1371/journal.pone.0146034.t002

###### Antimicrobial resistance and virulence genotypes of methicillin-resistant *Staphylococcus aureus* strains (*n* = 44) isolated from veterinarians in Australia.

![](pone.0146034.t002){#pone.0146034.t002g}

  Isolate                  Origin   Resistance genotype                                                           Virulence genotype
  ------------------------ -------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  **Clonal Complex 1**                                                                                            
  698                      STU      *blaZ-I-R*, *sdrM*                                                            *seh*, *sak*, *chp*, *scn*
  **Clonal Complex 5**                                                                                            
  616                      CAP      *blaZ-I-R*, *erm(A)*, *aadD*, *sdrM*, *fosB*                                  *sed*, *seg*, *sei*, *sej*, *sem*, *sen*, *seo*, *seq*, *ser*, *seu*
  **Clonal Complex 8**                                                                                            
  580                      CAP      *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  673                      CAP      *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *tet(M)*, *sdrM*, *fosB*                   *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  713                      EP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *seb*, *sek*, *seq*
  699                      EP       *blaZ-I-R*, *aacA-aphD*, *aadD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*             *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  718                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *aadD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*   *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  727                      EP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  741                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  761                      EP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  783                      EP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  787                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  823                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *aadD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*   *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  58                       EP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  55                       IND      *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *aadD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*   *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  389                      MP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *seb*, *sek*, *seq*
  747                      MPE      *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  612                      CAP      *blaZ-I-R*, *aacA-aphD*, *tet(K)*, *sdrM*, *fosB*                             *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  734                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *seb*, *sek*, *seq*, *sak*, *scn*
  742                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  822                      EP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  723                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  778                      EP       *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  570                      MP       *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  413                      MPE      *blaZ-I-R*, *erm(C)*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*           *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  716                      MPE      *blaZ-I-R*, *aacA-aphD*, *dfrA*, *tet(M)*, *sdrM*, *fosB*                     *sea*, *seb*, *sek*, *seq*, *sak*, *scn*
  **Clonal Complex 22**                                                                                           
  34                       CAP      *blaZ-I-R*, *vat(B)*, *fosB*                                                  *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  38                       CAP      *blaZ-I-R*, *vat(B)*, *fosB*                                                  *sec*, *seg*, *sei*, *sel*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  253                      CAP      *blaZ-I-R*, *fosB*                                                            *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  257                      CAP      *blaZ-I-R*, *erm(C)*                                                          *sec*, *seg*, *sei*, *sel*, *sem*, *sen*, *seo*, *seq*, *seu*
  330                      CAP      *blaZ-I-R*                                                                    *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*
  428                      CAP      *blaZ-I-R*                                                                    *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*, *chp*
  606                      CAP      *blaZ-I-R*                                                                    *sec*, *seg*, *sei*, *sel*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  610                      CAP      *blaZ-I-R*                                                                    *sec*, *seg*, *sei*, *sel*, *sem*, *seln*, *seo*, *seq*, *seu*
  622                      CAP      *blaZ-I-R*                                                                    *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  844                      CAP      *blaZ-I-R*                                                                    *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  809                      EP       *blaZ-I-R*                                                                    *sec*, *seg*, *sei*, *sel*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  100                      MPE      *blaZ-I-R*, *fosB*                                                            *seg*, *sei*, *sem*, *sen*, *seo*, *seq*, *seu*, *sak*, *chp*, *scn*
  **Clonal Complex 59**                                                                                           
  773                      MPE      *blaZ-I-R*, *msr(A)*, *mph(C)*, *sdrM*                                        *sea*, *seb*, *sek*, *seq*, *sak*, *chp*, *scn*
  **Clonal Complex 88**                                                                                           
  728                      EP       *blaZ-I-R*, *erm(A)*, *sdrM*                                                  *sec*, *sel*, *sak*, *scn*
  815                      EP       *blaZ-I-R*, *erm(A)*, *sdrM*                                                  *sak*, *scn*
  786                      HC       *blaZ-I-R*, *erm(A)*, *sdrM*                                                  *sec*, *sel*, *sak*, *scn*
  103                      MPE      *blaZ-I-R*, *sdrM*                                                            *sec*, *sel*, *sak*, *scn*
  **Clonal Complex 398**                                                                                          
  516                      PP       *blaZ-I-R*, *erm(C)*, *tet(K)*, *tet(M)*, *sdrM*, *fosB*                      *seg*

EP, equine practice; CAP, companion animal practice; MPE, mixed animal practice with both companion animals and equines; MP, mixed animal practice with companion animals and ruminants but no equines; PP, pig practice; HC, herd consulting practice; IND, industry veterinarian (pharmaceutical representative) with no clinical practice; STU, veterinary science student with undefined exposure.

Virulence gene data {#sec014}
-------------------

The carriage of virulence genes was also strongly influenced by the clonal complex ([Table 2](#pone.0146034.t002){ref-type="table"} and [S1 File](#pone.0146034.s001){ref-type="supplementary-material"}). The respective virulence gene profiles varied little for isolates belonging to CC8 and ST22. The majority of CC8 isolates possessed enterotoxin genes *seb+sek+seq* (24/24) (carried by *S*. *aureus* pathogenicity island 3 \[SaPI3\]) and the type D immune evasion cluster (IEC) (*sea*+*sak*+*scn*) (21/24). The 12 ST22 isolates possessed the enterotoxin *egc* cluster (*seg+sei+sem+sen+seo+seu)* carried by the ʊSaβ genomic island. Five of the isolates also harboured enterotoxins *sec+sel* (carried by SaPImw2). Eight isolates harboured a type B IEC (*sak+chp+scn*). None of the 44 isolates carried the toxic shock syndrome toxin 1 gene (*tst1*) or the Panton-Valentine Leukocidin (PVL) determinants *lukF* and *lukS*.

Statistical analysis of associations between isolate source and clonal complex of isolates {#sec015}
------------------------------------------------------------------------------------------

After excluding from consideration those veterinarians having exposure to more than one class of animal (i.e. mixed animal practitioners), a very strong positive association was found between veterinarians working exclusively with companion animals and carriage of ST22 MRSA, and those working exclusively with horses and carriage of CC8 MRSA. Isolates belonging to ST22 were more than 50 times more likely to be carried by a companion animal practitioner than another type of veterinarian (OR = 52.5, 95% CI = 5.2--532.7, *P* \< 0.001). Moreover, those belonging to CC8 were more than 17 times more likely to be carried by a veterinarian working exclusively with horses than another type of veterinarian (OR = 17.5, 95% CI = 3.3--92.5, *P* \< 0.001).

Discussion {#sec016}
==========

Recent advances in molecular analyses have facilitated a quantum leap in our understanding of the epidemiology of MRSA in animals and humans intimately exposed to animals. This study considered the molecular and antimicrobial resistance characteristics of MRSA isolated from Australian veterinarians. Foremost of the outcomes from the analyses was the dominance of MRSA strains belonging to CC8 and ST22 and their associations with distinct practice types (i.e. equine and companion animals, respectively), and a paucity of ST398, with only a single isolate obtained from a specialist pig practice veterinarian. Additionally, CC8 isolates from veterinarians with exposure to equine practice were more likely to be resistant to gentamicin and rifampicin, whereas ST22 isolates from veterinarians with exposure to companion animal practice were more likely to be resistant to fluoroquinolones.

CC8 MRSA has been observed as a cause of community-associated clinical infection in humans in the United States \[[@pone.0146034.ref025]\]. This clonal lineage has been isolated from horses and equine veterinarians in North America \[[@pone.0146034.ref007]\] and Europe \[[@pone.0146034.ref026]\] and appears much more adapted for survival among equine populations than other animal-associated MRSA clones \[[@pone.0146034.ref027]\]. In Australia, multiple CC8 community associated MRSA (CA-MRSA) clones have been described, including ST8-IV \[2B\] and ST612-IV \[2B\], however, the isolates are typically only resistant to the beta-lactam antimicrobials \[[@pone.0146034.ref028]\].

ST22 is considered an epidemic MRSA strain among human populations in Europe, and has been isolated from companion animals and companion animal veterinarians in this region \[[@pone.0146034.ref001],[@pone.0146034.ref029]\]. Similarly, ST22 MRSA is a leading cause of healthcare-associated MRSA infections in people in Australia \[[@pone.0146034.ref030]\] and has been isolated from Australian canines with skin and soft tissue infections (M. Barton, unpublished data). This clonal lineage is competent at "spilling over" from the human population into companion animals where it can persist for short periods of time, opportunistically cause clinical infections, and move bi-directionally \[[@pone.0146034.ref001]\].

The low prevalence of ST398 MRSA in veterinarians in this study is noteworthy as ST398 has been shown to be disseminated across multiple continents and colonises food animals, horses and people that are routinely exposed to animals \[[@pone.0146034.ref002],[@pone.0146034.ref031]\]. ST398 MRSA has previously been observed among livestock veterinarians in Europe and North America, \[[@pone.0146034.ref005],[@pone.0146034.ref032]\] with prevalence rates as high as 45% \[[@pone.0146034.ref005]\]. There are relatively few dedicated intensive livestock veterinarians in Australia in comparison to the main regions of intensive livestock production in Europe and North America. For example there are only about 100 members of the pig specialist interest group of the Australian Veterinary Association \[[@pone.0146034.ref033]\]. Annual surveillance studies of community-associated and healthcare-acquired MRSA infection have shown that ST398 MRSA is responsible for very few clinical cases of infection in humans in Australia \[[@pone.0146034.ref030],[@pone.0146034.ref034]\]. However, ST398 MRSA was detected among pigs in Australia during a contemporaneous study \[[@pone.0146034.ref016]\]. It is reasonable to expect that the organism may have further disseminated among the Australia pig herd and other potential host species, including humans in subsequent years. A follow up survey therefore seems warranted to determine if the prevalence has increased among veterinarians.

The high MRSA colonisation rates in companion animal and equine practice veterinarians in Australia could be associated with the handling and administration of antimicrobials in these animal species. This notion is supported by the high proportion of ST22 isolates showing resistance to fluoroquinolones, which is almost exclusively used in companion animals in Australia \[[@pone.0146034.ref035]\]. Moreover, a high proportion of CC8 isolates were resistant to gentamicin, which is frequently administered empirically to horses in Australia, and rifampicin which is exclusively used in combination with a macrolide to treat *Rhodococcus equi* infections in foals \[[@pone.0146034.ref014],[@pone.0146034.ref036]\]. Use of both antibiotics in horses (gentamicin by intravenous injection and rifampicin by oral administration to foals) could result in considerable opportunity for the veterinarian to be exposed to low levels of antimicrobials which could potentially influence the high prevalence of MRSA carriage in the Australian equine veterinary community \[[@pone.0146034.ref014],[@pone.0146034.ref037]\].

In addition to the CC8, ST22 and ST398 isolates a small number of CA-MRSA clones were identified including ST1-IV \[2B\] (WA1), in a veterinary student with undefined exposure, as well as two ST78-IV \[2B\] (WA2) isolates and one ST59-IV \[2B\]&5 (WA15). These three clones, particularly WA1 and WA2, are frequently isolated in Australia and therefore their detection is probably not associated with working in the animal industry \[[@pone.0146034.ref038],[@pone.0146034.ref039]\]. The USA100 isolate (ST5-II \[2A\]), is a major healthcare-associated clone in North America and in Japan/Korea. Rarely identified in Australia, patients colonised or infected with USA100 are usually epidemiologically linked to North America \[[@pone.0146034.ref040]\].

Conclusions {#sec017}
-----------

This study informed on the molecular and antimicrobial resistance characteristics of MRSA in veterinarians in Australia, allowing isolates to be placed into epidemiological and temporal context with strains from other sources both in Australia and abroad. Veterinarians predominantly carried MRSA CC8 and ST22, archetypes that have over the past decade become prolific colonisers, and under certain circumstances causes of clinical infections, in humans and some domestic species, worldwide. These findings may have implications for biosecurity and infection control programs in veterinary and public health settings in Australia.

Supporting Information {#sec018}
======================

###### The S1 File contains the full data set including isolate origin, clonal association, resistance and virulence gene data for all the isolates described in this study.

(XLSX)

###### 

Click here for additional data file.
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